Open AccessEfficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens
Author(s) -
К. V. Menshikov,
А. V. Sultanbaev,
Ш. И. Мусин,
А. А. Измайлов,
V. S. Chalov,
I. A. Menshikovа,
Н. И. Султанбаева,
E. V. Popova,
Д. О. Липатов
Publication year - 2022
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2022-16-9-85-92
Subject(s) - sunitinib , medicine , renal cell carcinoma , tyrosine kinase inhibitor , regimen , kidney cancer , oncology , adverse effect , contraindication , urology , pharmacology , gastroenterology , cancer , pathology , alternative medicine